We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesenVVeno Medical Corp

enVVeno Medical Corp

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
6.5 USD -0.02 ( 0.31%)
Last update at 2026-11-12T15:07:00Z
VOLUME
613
Market Cap
6.48M

Momentum Score

…

enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
6.50
Low
6.50
High
52 Week Price Range
8.67
Low
35.70
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

enVVeno Medical Corporation is a clinical-stage medical device company focused on treatments for chronic venous disease; public information on its pipeline and go-to-market plan is limited. Long-term growth drivers include an aging population, rising venous disease prevalence and progress on clinical and regulatory milestones, which may benefit investors seeking medtech exposure.

Key risks include adverse clinical or regulatory outcomes, the need for additional financing before commercialization, uncertain reimbursement and strong competition.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
6.52
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.03
ROE
-58.53%
Net Debt
-2.37M
ROCE
-70.96%
Diluted EPS TTM
-24.97

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -19.47M -21.82M -23.52M -24.67M -16.53M
Net income -19.47M -21.82M -23.52M -24.30M -16.20M
Selling general administrative 10.92M 11.58M 12.02M 15.02M 11.16M
Gross profit -0.49M -0.53M -0.55M - -
Reconciled depreciation 0.49M 0.53M 0.54M 0.53M 0.45M
Ebit -19.47M -21.82M -23.52M -24.93M -16.89M
Ebitda -18.98M -21.29M -22.97M -24.51M -16.75M
Depreciation and amortization 0.49M 0.53M 0.55M 0.42M 0.14M
Non operating income net other - - - 0.10M -
Operating income -20.90M -23.83M -25.24M -24.93M -16.89M
Other operating expenses 20.90M 23.83M 25.24M 24.93M 16.89M
Interest expense - - - 0.26M 0.02M
Interest income 0.69M 0.39M 0.17M 0.16M -
Net interest income 0.69M 0.39M 0.17M 0.16M 0.02M
Income tax expense - - - -0.36M -0.33M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 20.90M 23.30M 24.69M 24.93M 16.89M
Cost of revenue 0.49M 0.53M 0.55M - -
Total other income expense net 1.43M 2.01M 1.72M 0.26M 0.36M
Net income from continuing ops -19.47M -21.82M -24.05M -24.67M -16.53M
Net income applicable to common shares - - - -24.67M -16.53M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 29.56M 44.95M 48.63M 41.66M 57.70M
Other current assets 0.61M 0.58M 0.51M 0.39M 0.31M
Total liab 2.43M 2.79M 2.44M 2.93M 3.29M
Total stockholder equity 27.13M 42.16M 46.20M 38.73M 54.40M
Other current liab 1.37M 0.72M 1.03M 0.57M 0.06M
Common stock - - - - 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -171.33M -151.85M -130.04M -106.52M -81.85M
Other assets - - 0.00M 0.03M 0.05M
Cash 3.06M 1.75M 3.62M 4.55M 54.73M
Total current liabilities 2.12M 2.10M 1.37M 1.53M 1.58M
Current deferred revenue - - -0.43M - 0.67M
Net debt -2.37M -0.69M -2.22M -2.84M -52.72M
Short term debt 0.39M 0.36M 0.34M 0.31M 0.29M
Short long term debt total 0.70M 1.06M 1.40M 1.72M 2.01M
Other stockholder equity 198.46M 194.01M 176.24M 145.25M 136.26M
Property plant equipment - - - 0.52M 2.60M
Total current assets 28.83M 43.73M 46.92M 39.44M 55.04M
Net tangible assets - - - 38.73M 54.40M
Short term investments 25.15M 41.40M 42.79M 34.49M -
Accounts payable 0.36M 1.01M 0.43M 0.65M 0.56M
Retained earnings total equity - - - -106.52M -
Non currrent assets other 0.03M 0.03M 0.03M 0.03M 0.05M
Non current assets total 0.74M 1.22M 1.71M 2.23M 2.66M
Capital lease obligations 0.70M 1.06M 1.40M 1.72M 2.01M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 15.86M 1.33M 19.79M -34.44M -0.37M
Change to liabilities - - - 0.09M -0.83M
Total cashflows from investing activities 15.86M 1.33M -7.87M -34.55M -0.37M
Total cash from financing activities 1.02M 13.64M 25.79M 0.00M 57.61M
Change to operating activities - - - -0.51M -0.62M
Net income -19.47M -21.82M -23.52M -24.67M -16.53M
Change in cash 1.31M -1.87M -0.94M -50.17M 45.39M
Begin period cash flow 1.75M 3.62M 4.55M 54.73M 9.33M
End period cash flow 3.06M 1.75M 3.62M 4.55M 54.73M
Total cash from operating activities -15.57M -16.84M -18.86M -15.62M -11.85M
Issuance of capital stock 0.78M 13.59M 25.79M 0.00M 57.36M
Depreciation 0.49M 0.53M 0.55M 0.53M 0.45M
Other cashflows from financing activities 1.02M 0.05M -7.87M -34.55M 0.25M
Change to netincome - - - 9.05M 5.69M
Capital expenditures 0.01M 0.04M 0.03M 0.12M 0.37M
Cash and cash equivalents changes - - - -50.17M -
Change in working capital -0.40M 0.29M -0.62M -0.13M -1.14M
Stock based compensation 3.42M 4.14M 5.20M 8.99M 6.00M
Other non cash items 0.39M 0.02M -0.47M -0.34M -0.31M
Free cash flow -15.57M -16.88M -18.89M -15.73M -12.21M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVNO
enVVeno Medical Corp		 -0.02
0.31%		 6.50 - - 216.91 0.32 274.86 -0.87
ABT
Abbott Laboratories		 -0.71
0.65%		 108.58 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 0.28
0.28%		 101.89 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -2.16
0.68%		 316.63 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -
-%		 47.31 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

enVVeno Medical Corp

enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

70 Doppler, Irvine, CA, United States, 92618

949 261 2900

https://www.envveno.com

33

Name Title Year Born
Mr. Robert A. Berman CEO & Director 1963
Mr. Craig Thomas Glynn CFO, Treasurer & Sec. 1961
Dr. Marc H. Glickman M.D. Sr. VP & Chief Medical Officer 1949
Mr. Warren Hancock Co-founder NA
Dr. Benedict Broennimann M.D. Chief Medical Officer of Outside of United States 1957
Mr. Craig Thomas Glynn CFO, Treasurer & Secretary 1961
Dr. Hamed Alavi Ph.D. Senior VP & Chief Technology Officer NA
Dr. Marc H. Glickman M.D. Senior VP & Chief Medical Officer 1949
Mr. Andrew Cormack Chief Commercial Officer NA
Ms. Jennifer Bright CPA Chief Financial Officer 1971

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…